Rini Explores PD-1 Inhibition in Renal Cell Carcinoma

Video

For High-Definition, Click

Early clinical trials looking at the PD-1 inhibitor nivolumab demonstrated promising findings, sparking the initiation of several clinical trials, explains Brian I. Rini, MD. In the initial 34 patients with renal cell carcinoma (RCC) who were treated with nivolumab, the ORR was 29% and the overall survival (OS) rate was 50% at 2 years.

In a phase II dose-finding study, patients with RCC who received nivolumab experienced a median progression-free survival (PFS) of approximately 4 months. The objective response rate was near 20%, with a stable disease rate between 37% and 44% at the time of the analysis.

Based on a promising signal seen in melanoma, the combination of nivolumab and the CTLA-4 inhibitor ipilimumab was explored in a phase Ib study, notes Rini. In this trial, the ORR was 43% to 48% based on dose size. The median PFS was not reached, with a 24-week rate of approximately 65%.

A phase III trial is currently comparing nivolumab with the mTOR inhibitor everolimus in 822 patients with advanced or metastatic clear cell RCC who received 2 prior antiangiogenic therapies. The primary endpoint of the study is OS, with PFS as a secondary outcome measure.

Toxicity management with these agents differs significantly from what is commonly seen with TKIs, notes Rini. The immunotherapies activate the immune system against the tumor but also against healthy cells. This can cause liver function abnormalities and other unique side effects, cautions Rini.

Managing the unique adverse events associated with immunotherapy will likely be an initial barrier to the broader use of these therapies in clinical trials and the clinic, Rini believes. Side effect management education will be needed, in order to fully understand how to balance the risks and benefits of treatment with the novel therapies.

Related Videos
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Arya Amini, MD
Related Content
Professor Lindy Durrant

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

April 22nd 2024
Article
FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022
Podcast
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article
Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022
Podcast
Elizabeth Plimack, MD, MS, FASCO

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024
Article
Ritu Salani, MD

Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer

April 16th 2024
Article